羅傅倫 Steve Roffler
中央研究院生物醫學科學研究所特聘研究員
學歷
- 美國 University of California, Berkeley, Chemical Engineering 博士 (1986)
- 美國 University of Washington, Chemical Engineering 學士 (1981)
- 美國 Grays Harbor College, Engineering 科學副學士 (1978)
經歷
- 中央研究院生物醫學科學研究所特聘研究員 (2018/8 ～迄今)
- 中央研究院生物醫學科學研究所研究員 (2004/8 ～ 2018/8)
- 中央研究院生物醫學科學研究所副研究員 (1998/8 ～ 2004/7)
開發更安全及活躍的蛋白質療法 改善治療效果
Nanomedicines can improve cancer treatment by decreasing off target toxicities, but current technologies suffer from rapid leakage of drugs from nanocarriers before they reach their cellular targets, resulting in loss of efficacy and increased toxicity. We invented a chemical switch which responds to environmental conditions to alternate between a lipid-soluble state for efficient cargo loading and a water-soluble state for stable retention inside liposomes. A cue-responsive trigger(glycosidic switch) allows release of the molecular cargo at specific cellular sites. Glycosidic switch liposomes can cure mice bearing human breast cancer tumors.
The approach represents a general method to load and retain a range of molecular cargos inside liposomes, thereby offering new perspectives in engineering safe and effective liposomes for therapy and imaging.
We also developed monoclonal antibodies that specifically bind to polyethylene glycol, which is a biocompatible polymer often used in peptide, protein and nano-medicines(pegylation). These antibodies have been used by more than two hundred biotechnology and pharmaceutical companies throughout the world to accelerate the development of clinically used medicines including pegylated interferon alfa-2a for the treatment of hepatitis B and hepatitis C, pegylated epoetin beta for the treatment of anemia associated with chronic kidney diseases, and pegylated recombinant human granulocyte colony-stimulating factor for the treatment of neutropenia.
More recently, our anti-PEG antibodies were used for the development and safety assessment of the Moderna and Pfizer RNA vaccines against covid-19. We are using these antibodies to help understand how protein and nanomedicine drugs are affected by antibodies in our circulation to create drugs that display better safety profiles. We also co-invented technologies that utilize anti-PEG antibodies for the targeted delivery of pegylated peptides, proteins and nanomedicines to improve treatment selectivity and efficacy.
得獎感言
It is a great honor to receive the 傑出研究獎 from the Ministry of Science and Technology. This award encourages our lab to continue developing biotechnologies to improve patient health. I greatly appreciate the support from the Ministry of Science and Technology as well as from Academia Sinica, which has allowed us to carry out our studies.
I am lucky to work with motivated post-doctoral fellows, students and technicians. It is a pleasure to see their development, especially when they can logically think through problems. This award is largely attributable to their diligence and hard work. We have also been fortunate to collaborate with outstanding researchers at Academia Sinica and in universities throughout Taiwan.
However, my biggest thanks goes to my wife, Bing-Mae Chen, who has been my colleague, companion and supporter.
個人勵志銘
Try to make yourself better every day.
- 基礎研究超前部署
- 豐沛國家科研人才
